| Year |
Citation |
Score |
| 2020 |
Kim A, Dueker SR, Hwang JG, Yoon J, Lee SW, Lee HS, Yu BY, Yu KS, Lee H. An Investigation of the Metabolism and Excretion of KD101 and Its Interindividual Differences: A Microtracing Mass Balance Study in Humans. Clinical and Translational Science. PMID 33460293 DOI: 10.1111/Cts.12848 |
0.344 |
|
| 2020 |
Kim S, Kim S, Lee H. A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade). Drug Design, Development and Therapy. 14: 2831-2840. PMID 32764882 DOI: 10.2147/Dddt.S254776 |
0.319 |
|
| 2020 |
Lee JH, Faderl S, Pagel JM, Jung CW, Yoon SS, Pardanani AD, Becker PS, Lee H, Choi J, Lee K, Kim M, Cortes JE. Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. Blood Advances. 4: 2032-2043. PMID 32396615 DOI: 10.1182/Bloodadvances.2019000757 |
0.343 |
|
| 2020 |
Lee SW, Choi D, Heo M, Shin EC, Park SH, Kim SJ, Oh YK, Lee BH, Yang SH, Sung YC, Lee H. hIL-7-hyFc, a long-acting IL-7, increased absolute lymphocyte count in healthy subjects. Clinical and Translational Science. PMID 32339447 DOI: 10.1111/Cts.12800 |
0.351 |
|
| 2020 |
Kim A, Dueker SR, Dong F, Roffel AF, Lee SW, Lee H. Human ADME for YH12852 using wavelength scanning cavity ring-down spectroscopy (WS-CRDS) after a low radioactivity dose. Bioanalysis. 12: 87-98. PMID 31928227 DOI: 10.4155/Bio-2019-0119 |
0.333 |
|
| 2020 |
Huh KY, Shin W, Baek E, Seo S, Lee W, Baek S, Lee H. 948-P: A Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136, a Novel Long-Acting Glucagon Analogue, in Healthy Subjects Diabetes. 69. DOI: 10.2337/Db20-948-P |
0.406 |
|
| 2019 |
Lee HA, Yu KS, Park SI, Yoon S, Onohara M, Ahn Y, Lee H. URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers. Rheumatology (Oxford, England). PMID 31056705 DOI: 10.1093/Rheumatology/Kez140 |
0.354 |
|
| 2019 |
Kim Y, Hatley O, Rhee SJ, Yi S, Lee HA, Yoon S, Chung JY, Yu KS, Lee H. Development of a Korean-specific virtual population for physiologically-based pharmacokinetic modeling and simulation. Biopharmaceutics & Drug Disposition. PMID 30921829 DOI: 10.1002/Bdd.2178 |
0.323 |
|
| 2019 |
Lee HA, Lee KR, Jang SB, Chung SY, Yu KS, Lee H. A physiologically-based pharmacokinetic model adequately predicted the human pharmacokinetic profiles of YH4808, a novel K-competitive acid blocker. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. PMID 30641142 DOI: 10.1016/J.Ejps.2019.01.009 |
0.362 |
|
| 2019 |
Polasek TM, Rostami-Hodjegan A, Yim DS, Jamei M, Lee H, Kimko H, Kim JK, Nguyen PTT, Darwich AS, Shin JG. What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing. The Aaps Journal. 21: 17. PMID 30627939 DOI: 10.1208/S12248-018-0286-6 |
0.374 |
|
| 2019 |
Lee SW, Choi D, Heo M, Shin E, Park S, Kim SJ, Lee BH, Yang SH, Sung YC, Lee H. Abstract CT045: Hyleukin-7, a long-acting interleukin-7, increased absolute lymphocyte counts after subcutaneous and intramuscular administration in healthy subjects Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ct045 |
0.404 |
|
| 2017 |
Kim YK, Kim A, Park SJ, Lee H. New tablet formulation of tacrolimus with smaller interindividual variability may become a better treatment option than the conventional capsule formulation in organ transplant patients. Drug Design, Development and Therapy. 11: 2861-2869. PMID 29033547 DOI: 10.2147/Dddt.S142201 |
0.355 |
|
| 2017 |
Kim Y, Kim A, Lee S, Choi SH, Lee DY, Song JS, Lee H, Jang IJ, Yu KS. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-Dose Administration in Healthy Korean Male Subjects. Clinical Therapeutics. PMID 28865799 DOI: 10.1016/J.Clinthera.2017.08.002 |
0.347 |
|
| 2017 |
Lee H, Chung H, Lee S, Lee H, Yang SM, Yoon SH, Cho JY, Jang IJ, Yu KS. LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. PMID 28551775 DOI: 10.1007/S40259-017-0230-9 |
0.308 |
|
| 2017 |
Rhee SJ, Lee JW, Yu KS, Hong KT, Choi JY, Ry Hong C, Park KD, Shin HY, Song SH, Kang HJ, Lee H. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram. American Journal of Hematology. PMID 28370238 DOI: 10.1002/Ajh.24734 |
0.4 |
|
| 2017 |
Kim A, Yu BY, Dueker SR, Shin KH, Kim HS, Ahn H, Cho JY, Yu KS, Jang IJ, Lee H. An accelerator mass spectrometry-enabled microtracer study to evaluate the first-pass effect on the absorption of YH4808. Clinical Pharmacology and Therapeutics. PMID 28214288 DOI: 10.1002/Cpt.672 |
0.392 |
|
| 2016 |
Suh HY, Peck CC, Yu KS, Lee H. Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. Drug Design, Development and Therapy. 10: 4005-4016. PMID 27994442 DOI: 10.2147/Dddt.S121520 |
0.361 |
|
| 2016 |
Kim A, Lim KS, Lee H, Chung H, Yoon SH, Yu KS, Cho JY, Jang IJ, Chung JY. A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. International Clinical Psychopharmacology. PMID 26950553 DOI: 10.1097/Yic.0000000000000124 |
0.405 |
|
| 2016 |
Choi Y, Jiang F, An H, Park HJ, Choi JH, Lee H. A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMET(TM) Plus platform. The Pharmacogenomics Journal. PMID 26882121 DOI: 10.1038/Tpj.2015.99 |
0.301 |
|
| 2016 |
Lee KW, Oh D, Han S, Kim JW, Shin J, Jo S, Kim NH, Woo A, Won J, Hahn S, Lee H, Kim WH, Bang Y. A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors. Journal of Clinical Oncology. 34: 2521-2521. DOI: 10.1200/Jco.2016.34.15_Suppl.2521 |
0.373 |
|
| 2015 |
Yoon S, Shin D, Lee H, Jang IJ, Yu KS. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Design, Development and Therapy. 9: 5033-49. PMID 26357467 DOI: 10.2147/Dddt.S86884 |
0.422 |
|
| 2015 |
Chung H, Lee H, Han H, An H, Lim KS, Lee Y, Cho JY, Yoon SH, Jang IJ, Yu KS. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles. Drug Design, Development and Therapy. 9: 2609-16. PMID 25999694 DOI: 10.2147/Dddt.S80066 |
0.392 |
|
| 2015 |
Park SI, Lee H, Oh J, Lim KS, Jang IJ, Kim JA, Jung JH, Yu KS. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects. Drug Design, Development and Therapy. 9: 729-36. PMID 25678778 DOI: 10.2147/Dddt.S75980 |
0.393 |
|
| 2014 |
Lee J, Lee H, Jang K, Lim KS, Shin D, Yu KS. Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers. Drug Design, Development and Therapy. 8: 1781-8. PMID 25336921 DOI: 10.2147/Dddt.S68574 |
0.407 |
|
| 2014 |
Lee J, Yoon S, Shin D, Han H, An H, Lee J, Lim KS, Yu KS, Lee H. Predictive performance of gentamicin dosing nomograms. Drug Design, Development and Therapy. 8: 1097-106. PMID 25152616 DOI: 10.2147/Dddt.S66981 |
0.393 |
|
| 2014 |
Jang K, Yoon S, Kim SE, Cho JY, Yoon SH, Lim KS, Yu KS, Jang IJ, Lee H. Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state. Drug Design, Development and Therapy. 8: 851-8. PMID 25028536 DOI: 10.2147/Dddt.S62176 |
0.368 |
|
| 2014 |
Yoon S, Lee H, Kim TE, Lee S, Chee DH, Cho JY, Yu KS, Jang IJ. Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers. Drug Design, Development and Therapy. 8: 123-8. PMID 24470753 DOI: 10.2147/Dddt.S53027 |
0.365 |
|
| 2014 |
Shin KH, Lim KS, Lee H, Jang IJ, Yu KS. An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects. Investigational New Drugs. 32: 636-43. PMID 24468886 DOI: 10.1007/S10637-014-0068-7 |
0.377 |
|
| 2013 |
Lee H, Jang IJ, Yu KS, Choi J, Oh BH. A Population Pharmacokinetic Analysis of Fimasartan, a Selective Angiotensin II Receptor Antagonist, in Healthy Caucasian Subjects and Korean Patients With Hypertension. Clinical Pharmacology in Drug Development. 2: 162-72. PMID 27121670 DOI: 10.1002/Cpdd.10 |
0.351 |
|
| 2013 |
Cha YJ, Lee H, Gu N, Kim TE, Lim KS, Yoon SH, Chung JY, Jang IJ, Shin SG, Yu KS, Cho JY. Sustained Increase in the Oral Bioavailability of Loperamide after a Single Oral Dose of HM30181, a P-glycoprotein Inhibitor, in Healthy Male Participants. Basic & Clinical Pharmacology & Toxicology. 113: 419-24. PMID 23829508 DOI: 10.1111/Bcpt.12108 |
0.414 |
|
| 2012 |
Lee H, Yang HM, Lee HY, Kim JJ, Choi D, Seung KB, Jeon ES, Ha JW, Rim SJ, Park JB, Shin JH, Oh BH. Efficacy and Tolerability of Once-Daily Oral Fimasartan 20 to 240 mg/d in Korean Patients with Hypertension: Findings from Two Phase II, Randomized, Double-Blind, Placebo-Controlled Studies Clinical Therapeutics. 34: 1273-1289. PMID 22608107 DOI: 10.1016/J.Clinthera.2012.04.021 |
0.398 |
|
| 2011 |
Chi YH, Lee H, Paik SH, Lee JH, Yoo BW, Kim JH, Tan HK, Kim SL. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects. American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions. 11: 335-46. PMID 21910510 DOI: 10.2165/11593840-000000000-00000 |
0.423 |
|
| 2011 |
Xie HG, Cao YJ, Gauda EB, Agthe AG, Hendrix CW, Lee H. Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. Journal of Clinical Pharmacology. 51: 502-11. PMID 20484620 DOI: 10.1177/0091270010370587 |
0.323 |
|
| 2009 |
Xu Z, Vu T, Lee H, Hu C, Ling J, Yan H, Baker D, Beutler A, Pendley C, Wagner C, Davis HM, Zhou H. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. Journal of Clinical Pharmacology. 49: 1056-70. PMID 19617465 DOI: 10.1177/0091270009339192 |
0.365 |
|
| 2008 |
Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Therapeutic Drug Monitoring. 30: 674-81. PMID 19057371 DOI: 10.1097/Ftd.0B013E31818B6B2F |
0.361 |
|
| 2006 |
Tannenbaum SJ, Holford NHG, Lee H, Peck CC, Mould DR. Simulation of correlated continuous and categorical variables using a single multivariate distribution Journal of Pharmacokinetics and Pharmacodynamics. 33: 773-794. PMID 17053984 DOI: 10.1007/S10928-006-9033-1 |
0.302 |
|
| 2005 |
Lee H, Yim DS, Zhou H, Peck CC. Evidence of effectiveness: how much can we extrapolate from existing studies? The Aaps Journal. 7: E467-74. PMID 16353924 DOI: 10.1208/Aapsj070247 |
0.333 |
|
| 2005 |
Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. Journal of Clinical Pharmacology. 45: 246-56. PMID 15703360 DOI: 10.1177/0091270004271945 |
0.384 |
|
| 2005 |
Lee H, Yim D, Green B, Peck C. Modeling circadian rhythm of diastolic blood pressure in hypertensive patients using 24‐hour ambulatory blood pressure monitoring Clinical Pharmacology & Therapeutics. 77. DOI: 10.1016/J.Clpt.2004.12.109 |
0.311 |
|
| 2004 |
Berry NS, Yim D, Peck CC, Weiner DL, Lee H. A systematic approach to identifying and modeling the source of pharmacokinetic (PK) non‐linearity Clinical Pharmacology & Therapeutics. 75: 90. DOI: 10.1016/J.Clpt.2003.11.346 |
0.38 |
|
| 2004 |
Lee H, Yim D, Nestorov I, Zhou H, Buckwalter M, Peck CC. 0.8 mg/kg once weekly subcutaneous regimen of etanercept will yield an overlapping steady state time‐concentration profile with 0.4 mg/kg twice weekly dosing in pediatric patients with juvenile rheumatoid arthritis (JRA) Clinical Pharmacology & Therapeutics. 75: 53. DOI: 10.1016/J.Clpt.2003.11.201 |
0.368 |
|
| 2004 |
Yim D, Lee H, Netorov I, Zhou H, Buckwalter M, Peck CC. A population pharmacokinetic (PK) analysis of etanercept in patients with juvenile rheumatoid arthritis (JRA) Clinical Pharmacology & Therapeutics. 75: 53. DOI: 10.1016/J.Clpt.2003.11.199 |
0.367 |
|
| 2003 |
Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis Clinical Pharmacology & Therapeutics. 73: 348-365. PMID 12709725 DOI: 10.1016/S0009-9236(02)17635-1 |
0.387 |
|
| 2002 |
Cross J, Lee H, Westelinck A, Nelson J, Grudzinskas C, Peck C. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiology and Drug Safety. 11: 439-446. PMID 12426927 DOI: 10.1002/Pds.744 |
0.302 |
|
| Show low-probability matches. |